Is $CLOV one of the most undervalued healthcare stocks?

Clover Health (CLOV) is not one of the most undervalued healthcare stocks based on the screening criteria used in the query. Here's the analysis:

1. High P/E Ratio: Clover Health has a P/E ratio of -4.69, which is considered high and suggests that the stock is overvalued relative to its earnings.

2. Low P/B Ratio: The Price-to-Book (P/B) ratio of 2.56 indicates that the stock is not significantly overvalued based on its book value.

3. Low Price: The closing price of $1.51 is lower than many other healthcare stocks, which could make it appear undervalued at first glance.

4. Market Capitalization: The market capitalization of Clover Health is not provided in the data, but it is likely to be small based on its low price and P/E ratio. Small-cap stocks can be more volatile and riskier than larger companies.

Based on these points, while Clover Health may seem undervalued due to its low price, the high P/E ratio suggests that it is actually overvalued relative to its earnings. The P/B ratio indicates that it is not overvalued based on its book value, but this alone does not make it one of the most undervalued stocks in the healthcare sector.